Mosedipimod

DB12592InvestigationalSmall molecule

Mosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.

Mechanism: Mosedipimod is a proprietary compound originally derived from Sika deer antler. It accelerates endocytic trafficking of Pattern Recognition Receptors which allows for the swift removal of PAMPs/DAMPs. This drug has been shown to improve lung function and reduce inflammation and fibrosis in animal models. Currently, mosedipimod is being investigated against chemoradiation-induced oral mucositis and neutropenia, as well as against COVID-19.
Curator reviewed
Formula / weight: C₃₉H₇₀O₆ · 634.983 g/mol (avg)
Code names: EC-18 · WHO 10702

Resolves to

Compound

Structure

InChIKeyGAKUNXBDVGLOFS-DUZKARGPSA-NSMILESCCCCCCCCCCCCCCCC(=O)OCC(COC(C)=O)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC

Targets

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mosedipimod, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.